Results 121 to 130 of about 1,197 (187)
Wide implications of a trial on pitolisant for cataplexy [PDF]
The Lancet Neurology, 2017 openaire +3 more sources
Treatment paradigms for cataplexy in narcolepsy: past, present, and future [PDF]
core +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pitolisant: Pediatric First Approval
Pediatric Drugs, 2023Pitolisant (WAKIX®), a histamine H3 receptor antagonist/inverse agonist that has been developed by Bioprojet Pharma, is approved in the EU and USA and elsewhere for use in adults with narcolepsy with or without cataplexy. In February 2023, based on clinical data in patients aged 6 to < 18 years, pitolisant received its first approval in adolescents and
S. Keam
semanticscholar +3 more sources
CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.Alcohol use disorder (AUD) is a chronic condition marked by compulsive drinking and withdrawal‐related negative affect. Histamine (HA) signaling, particularly via the histamine H3 receptor (H3R), may modulate alcohol‐related behaviors.
Yan Zhao +13 more
semanticscholar +2 more sources
Exploring Polymorphism: Hydrochloride Salts of Pitolisant and Analogues
Crystal Growth & DesignPitolisant hydrochloride is used to treat excessive daytime sleepiness in adults with narcolepsy. The drug is formulated as a crystalline solid, and a monoclinic P21 form has been claimed in patents, but little additional information about the structure and polymorphism of the compound has been published.
J. Patel +13 more
semanticscholar +2 more sources
Pitolisant: A Game Changer for Managing Sleepiness in OSA?
CHESTGonzalo Labarca, Bhajan Singh
semanticscholar +4 more sources